Hanmi Pharmaceutical: Robust Core Business Growth, But Target Price Lowered”…Why?
iM Securities lowered Hanmi Pharmaceutical's target price due to a projected weak Q1 performance, but noted that its core business growth remains robust.
Key takeaway
"Hanmi Pharmaceutical: Robust Core Business Growth, But Target Price Lowered”…Why?" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 5 out of 100. iM Securities lowered Hanmi Pharmaceutical's target price due to a projected weak Q1 performance, but noted that its core business growth remains robust. Reported by Maeil Business on April 13, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.